| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10076555 | CLIVUNEL INC | Methods of inducing melanogenesis in a subject |
Feb, 2025
(9 months from now) | |
| US8334265 | CLIVUNEL INC | Method of treatment of photodermatoses |
Mar, 2029
(4 years from now) | |
Scenesse is owned by Clivunel Inc.
Scenesse contains Afamelanotide.
Scenesse has a total of 2 drug patents out of which 0 drug patents have expired.
Scenesse was authorised for market use on 08 October, 2019.
Scenesse is available in implant;subcutaneous dosage forms.
Scenesse can be used as increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (epp).
Drug patent challenges can be filed against Scenesse from 09 October, 2023.
The generics of Scenesse are possible to be released after 11 March, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-270) | Oct 08, 2026 |
| New Chemical Entity Exclusivity(NCE) | Oct 08, 2024 |
Drugs and Companies using AFAMELANOTIDE ingredient
NCE-1 date: 09 October, 2023
Market Authorisation Date: 08 October, 2019
Treatment: Increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (epp)
Dosage: IMPLANT;SUBCUTANEOUS
SCENESSE family patents
